Risk of no-reflow in culprit lesion versus culprit vessel PCI in acute STEMI

Coronary Artery Disease

Volumn 26, Issue 6, 2015, Pages 510-515

  Arslan, Uʇur ^a   Yaman, Mehmet ^a   Kocaoʇlu, Ibrahim ^b   Turan, Oʇuzhan Ekrem ^b   Yücel, Huriye ^a   Aksakal, Aytekin ^a   Günaydin, Ilksen Atasoy ^a   Ateş, Ahmet Hakan ^a  

^a Department of Microbiology and Clinical Microbiology   (Turkey)

^b Aydin 82 Yil State Hospital   (Turkey)

Author keywords

culprit lesion; culprit vessel; myocardial infarction; primary percutaneous coronary intervention; thrombolysis in myocardial infarction flow

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TIROFIBAN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY STENT; CORONARY STENTING; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; ADVERSE EFFECTS; AGED; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; CORONARY RESTENOSIS; DEVICES; KAPLAN MEIER METHOD; MULTICENTER STUDY; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PATHOPHYSIOLOGY; PROCEDURES; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; STENT; TREATMENT OUTCOME; TURKEY;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CORONARY RESTENOSIS; CORONARY VESSELS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PLAQUE, ATHEROSCLEROTIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STENTS; TREATMENT OUTCOME; TURKEY;

EID: 84938935795     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000277     Document Type: Article

References (21)

1. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619
2. O'Gara PT, Kushner FG, Ascheim DD, Casey De Jr, Chung MK, De Lemos JA, et al. CF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: 529-555
3. Vlaar PJ, Mahmoud KD, Holmes DR Jr, Van Valkenhoef G, Hillege HL, Van Der Horst IC, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-Analysis. J Am Coll Cardiol 2011; 58: 692-703
4. Hannan EL, Samadashvili Z, Walford G, Holmes DR Jr, Jacobs AK, Stamato NJ, et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv 2010; 3: 22-31
5. Toma M, Buller CE, Westerhout CM, Fu Y, O'Neill WW, Holmes DR Jr, et al. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J 2010; 31: 1701-1707
6. Widimsky P, Holmes DR Jr. How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease?. Eur Heart J 2011; 32: 396-403
7. Corpus RA, House JA, Marso SP, Grantham JA, Huber KC Jr, Laster SB, et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J 2004; 148: 493-500
8. Qarawani D, Nahir M, Abboud M, Hazanov Y, Hasin Y. Culprit only versus complete coronary revascularization during primary PCI. Int J Cardiol 2008; 123: 288-292
9. Hudzik B. Prognostic impact of complete revascularization and diabetes mellitus in patients with acute myocardial infarction and multivessel coronary artery disease. Eur Heart J 2009; 30 (Suppl 1): 95
10. Politi L, Sgura F, Rossi R, Monopoli D, Guerri E, Leuzzi C, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term followup. Heart 2010; 96: 662-667
11. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013; 369: 1115-1123
12. Gershlich AH. on behalf of the CvLPRIT investigators. Complete versus Lesion only PRimary -PCI Trial (CvLPRIT): Treat the infarct related artery only or all lesions. ESC 2014 Hotline: Myocardial Infarction session, Barcelona
13. Bainey KR, Mehta SR, Lai T, Welsh RC. Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and meta-Analysis. Am Heart J 2014; 167: 1-14
14. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995; 130: 239-243
15. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-2518
16. Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, Eteiba H, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol 2014; 63: 2088-2098
17. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-292
18. Briasoulis A, Afonso L, Palla M, Sharma S, Panaich S, Papageorgiou N, Tousoulis D. Culprit-vessel versus complete revascularization during primary angioplasty in ST-elevation myocardial infarction: an updated meta-Analysis. Int J Cardiol 2015; 178: 171-174
19. Rigattieri S, Biondi-Zoccai G, Silvestri P, Di Russo C, Musto C, Ferraiuolo G, Loschiavo P. Management of multivessel coronary disease after ST elevation myocardial infarction treated by primary angioplasty. J Interv Cardiol 2008; 21: 1-7
20. Varani E, Balducelli M, Aquilina M, Vecchi G, Hussien MN, Frassineti V, Maresta A. Single or multivessel percutaneous coronary intervention in STelevation myocardial infarction patients. Catheter Cardiovasc Interv 2008; 72: 927-933
21. Mohamad T, Bernal JM, Kondur A, Hari P, Nelson K, Niraj A, et al. Coronary revascularization strategy for ST elevation myocardial infarction with multivessel disease: experience and results at 1-year follow-up. Am J Ther 2011; 18: 92-100